Company updates plans for commercial vaccine manufacturing facility in Hamilton
Dennis Bragg photo
and last updated 2021-06-25 01:55:36-04
HAMILTON â A New Jersey-based pharmaceuticals company says its on track to build a new, commercial scale vaccine manufacturing facility in the Bitterroot Valley.
Tonix Pharmaceuticals first announced plans to locate one of its operations on the east side of Hamilton last winter. And this week, company officials are in town for further discussions with Ravalli County and Hamilton leaders.
Plans are to build on 44-acres of land off Old Corvallis Highway in the Targeted Economic Development District, or TEDD, organized by the county, city and the Ravalli County Economic Development Authority.
Share:
Interim Analysis of Second Confirmatory Phase 3 Study in Fibromyalgia
Expected in Third Quarter 2021
Deep Pipeline Progressing with Three Central Nervous System
(CNS) Programs Expected to Enter Phase 2 Trials This Year
At March 31, 2021, Cash and Cash Equivalents Totaled Approximately $164 Million
CHATHAM, N.J., May 10, 2021 (GLOBE NEWSWIRE) Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021 and provided an overview of recent operational highlights. Tonix possesses a deep pipeline of high-value programs ranging from preclinical to mid-Phase 3 development, with three CNS programs poised to enter Phase 2 trials this year, said Seth Lederman, M.D., President and Chief Executive Officer. Our strategy is to in-license, acquire or internally invent high impact therapeutic programs which we can validate, de-risk and advance
GB Sciences Featured & Speaking at the SACHS Associates 4th Annual Neuroscience Innovation Forum
LAS VEGAS, NV / ACCESSWIRE / April 27, 2021 / GB Sciences (GBS), Inc. (OTCQB:GBLX), a leading phytomedicine research and biopharmaceutical development company, will be featured during the SPOTLIGHT SHOWCASE at the SACHS Associates 4th Annual Neuroscience Innovation Forum (NIF) for Business Development, Licensing & Investment from April 28 to April 30. The SACHS NIF, which is entirely virtual, will include a SPOTLIGHT SHOWCASE session describing GB Sciences recent pivot and novel drug development pipeline. In addition, Dr. Andrea Small-Howard, the Chief Science Officer and Director of GB Sciences, is an invited speaker on the Pain, Migraines, and Addiction Panel during a live session on Therapeutics Day 2, April 29 at 11:50 a.m. EDT.